ORIGINAL ARTICLECorrelates for Completion of 3-Dose Regimen of HPV Vaccine in Female Members of a Managed Care Organization
Section snippets
PARTICIPANTS AND METHODS
As the largest managed care organization in southern California, KPSC serves more than 3 million members. Members of KPSC are broadly representative of the diverse racial/ethnic and socioeconomic backgrounds of the source population in southern California. By nature of the prepaid managed care system, members of KPSC have relatively equal health care coverage. In particular, HPV4 is offered to eligible female members without additional out-of-pocket cost (variations in office visit copay exist
RESULTS
A total of 34,193 females aged 9 through 26 years received the first dose of HPV4 between October 2006 and March 2007 (ie, 9.5% of all female members in this age range who maintained health plan membership during that period), and 29,598 maintained their health plan membership for the following 12 months. These 29,598 females (24,676 in the 9- to 17-year-old age group and 4922 in the 18- to 26-year-old age group) were included in the study. Among them, 12,663 (42.8%) completed the 3-dose
DISCUSSION
In the current study, the rate of completion of the 3-dose regimen of HPV4 in a 12-month period was less than 50% among those who initiated the vaccination. Higher neighborhood education levels, Medi-Cal status for adolescent girls, and history of allergy were positive predictors for regimen completion. In contrast, black and Hispanic adolescent girls, young women who had a pediatrician PCP, and a history of hospitalizations/emergency department visits were correlates for nonadherence to the
CONCLUSION
Black and Hispanic adolescent girls, females who reside in neighborhoods with lower average education levels, young women who have a pediatrician PCP, and those with histories of several hospitalizations/emergency department visits were less likely to complete the 3-dose regimen of HPV4. These findings provide useful insight for developing public health programs to enhance proper HPV vaccination, targeting populations susceptible to nonadherence. Of note, our findings represent the early
REFERENCES (11)
- et al.
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
Lancet Oncol
(2005) - et al.
Limitations and potential uses of census-based data on ethnicity in a diverse community
Ann Epidemiol
(2004) - et al.
Attitudes about human papillomavirus vaccine among family physicians
J Pediatr Adolesc Gynecol
(2005) - et al.
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
Br J Cancer
(2006 Dec 4) - et al.
Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Recomm Rep
(2007)
Cited by (76)
Factors influencing Human papillomavirus (HPV) vaccination series completion in Mississippi Medicaid
2020, VaccineCitation Excerpt :There were disparities in HPV vaccine completion based on age, gender and race/ethnicity in our study. Younger age has consistently been reported as a significant predictor of series completion across most previous studies [13,15,16,27,29–31]. CDC-funded VFC program pays for vaccinations for children below 19 years of age that qualify for Medicaid, are uninsured, or are American Indian/Alaskan Native [23].
Predictors of Human Papillomavirus Vaccine Completion Among Low-Income Latina/o Adolescents
2019, Journal of Adolescent Health
This work was supported by a research grant from Merck & Co, Inc [EPI08014.036.02]. Drs Chao, Slezak, and Jacobsen received research funding from Merck & Co, Inc, to work on this study and a related study, and Dr Jacobsen is an unpaid consultant for Merck & Co, Inc. Dr Velicer is an employee of Merck & Co, Inc.